Abstract: Contact dermatitis (CD) is a common cutaneous inflammatory condition that affects millions of people worldwide. Xenobiotic agents are frequently encountered in substances used in everyday life, making it difficult to avoid personal and occupational exposure. Toll-like receptors (TLRs) are transmembrane receptors that modulate the innate immune system in response to tissue injury or infection. TLRs play a key role in the pathophysiology of contact dermatitis. TLR signaling is involved in three major forms of CD: protein CD, allergic contact dermatitis (ACD), and irritant CD. Of the 10 TLRs found in humans, three play an important role in ACD. This makes TLRs a useful potential therapeutic target to consider against CD. In this review, we discuss the role of TLRs in CD and summarize current and emerging treatments for CD that target TLRs.
Get full access to this article
View all access options for this article.
References
1.
KaishoT, AkiraS. Toll-like receptor function and signaling. J Allergy Clin Immunol. 2006; 117(5):979–987; quiz 988; doi: 10.1016/j.jaci.2006.02.023
2.
LepperPM, TriantafilouM, O’NeillLA, et al.Modulation of toll-like receptor signalling as a new therapeutic principle. Mediators Inflamm. 2010; 2010:705612–705612; doi: 10.1155/2010/705612
3.
KabelitzD, MedzhitovR. Innate immunity—cross-talk with adaptive immunity through pattern recognition receptors and cytokines. Curr Opin Immunol. 2007; 19(1):1–3; doi: 10.1016/j.coi.2006.11.018
4.
AinscoughJS, Frank GerberickG, DearmanRJ, et al.Danger, intracellular signaling, and the orchestration of dendritic cell function in skin sensitization. J Immunotoxicol. 2013; 10(3):223–234; doi: 10.3109/1547691X.2012.711782
5.
LemaitreB, NicolasE, MichautL, et al.The dorsoventral regulatory gene cassette spätzle/toll/cactus controls the potent antifungal response in drosophila adults. Cell. 1996; 86(6):973–983; doi: 10.1016/S0092-8674(00)80172-5
6.
PoltorakA, HeX, SmirnovaI, et al.Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene. Science. 1998; 282(5396):2085–2088; doi: 10.1126/science.282.5396.2085
7.
MedzhitovR, Preston-HurlburtP, JanewayCA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997; 388(6640):394–397; doi: 10.1038/41131
8.
O’NeillLAJ, GolenbockD, BowieAG. The history of Toll-like receptors—redefining innate immunity. Nat Rev Immunol. 2013; 13(6):453–460; doi: 10.1038/nri3446
9.
BehzadiP, García-PerdomoHA, KarpińskiTM. Toll-Like Receptors: General Molecular and Structural Biology. J Immunol Res. 2021; 2021:9914854; doi: 10.1155/2021/9914854
10.
SameerAS, NissarS. Toll-like receptors (TLRs): Structure, functions, signaling, and role of their polymorphisms in colorectal cancer susceptibility. Biomed Res Int. 2021; 2021:1157023; doi: 10.1155/2021/1157023
11.
MichelsKR, LukacsNW, FonsecaW. TLR Activation and Allergic Disease: Early Life Microbiome and Treatment. Curr Allergy Asthma Rep. 2018; 18(11):61; doi: 10.1007/s11882-018-0815-5
12.
LaiCY, SuYW, LinKI, et al.Natural modulators of endosomal toll-like receptor-mediated psoriatic skin inflammation. J Immunol Res. 2017; 2017:7807313–7807315; doi: 10.1155/2017/7807313
13.
DuanT, DuY, XingC, et al.Toll-like receptor signaling and its role in cell-mediated immunity. Front Immunol. 2022; 13:812774; doi: 10.3389/fimmu.2022.812774
14.
KumarV. Toll-like receptors in the pathogenesis of neuroinflammation. J Neuroimmunol. 2019; 332:16–30; doi: 10.1016/j.jneuroim.2019.03.012
BrarKK. A review of contact dermatitis. Ann Allergy Asthma Immunol. 2021; 126(1):32–39; doi: 10.1016/j.anai.2020.10.003
18.
DiepgenTL, OfenlochRF, BruzeM, et al.Prevalence of contact allergy in the general population in different European regions. Br J Dermatol. 2016; 174(2):319–329; doi: 10.1111/bjd.14167
AlinaghiF, BennikeNH, EgebergA, et al.Prevalence of contact allergy in the general population: A systematic review and meta‐analysis. Contact Dermatitis. 2019; 80(2):77–85; doi: 10.1111/cod.13119
LevinC, WarshawE. Protein contact dermatitis: Allergens, pathogenesis, and management. Dermatitis. 2008; 19(5):241–251; doi: 10.2310/6620.2008.08006
23.
VeienNK, HattelT, JustesenO, et al.Causes of eczema in the food industry. Derm Beruf Umwelt. 1983; 31(3):84–86.
24.
PeanaM, ZdybK, MediciS, et al.Ni(II) interaction with a peptide model of the human TLR4 ectodomain. J Trace Elem Med Biol. 2017; 44:151–160; doi: 10.1016/j.jtemb.2017.07.006
25.
TrompetteA, DivanovicS, VisintinA, et al.Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein. Nature. 2009; 457(7229):585–588; doi: 10.1038/nature07548
26.
ShimazuR, AkashiS, OgataH, et al.MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like Receptor 4. J Exp Med. 1999; 189(11):1777–1782; doi: 10.1084/jem.189.11.1777
27.
ThomasWR. Molecular mimicry as the key to the dominance of the house dust mite allergen Der p 2. Expert Rev Clin Immunol. 2009; 5(3):233–237; doi: 10.1586/eci.09.5
28.
TsaiJJ, LiuSH, YinSC, et al.Mite allergen Der-p2 triggers human B lymphocyte activation and Toll-Like Receptor-4 induction. PLoS One. 2011; 6(9):e23249; doi: 10.1371/journal.pone.0023249
McFaddenJP, PuangpetP, BasketterDA, et al.Why does allergic contact dermatitis exist? Br J Dermatol. 2013; 168(4):692–699; doi: 10.1111/bjd.12145
31.
PeiserM, TralauT, HeidlerJ, et al.Allergic contact dermatitis: Epidemiology, molecular mechanisms, in vitro methods and regulatory aspects. Cell Mol Life Sci. 2012; 69(5):763–781; doi: 10.1007/s00018-011-0846-8
32.
NassauS, FonacierL. Allergic contact dermatitis. Med Clin North Am. 2020; 104(1):61–76; doi: 10.1016/j.mcna.2019.08.012
33.
KaplanDH, IgyártóBZ, GaspariAA. Early immune events in the induction of allergic contact dermatitis. Nat Rev Immunol. 2012; 12(2):114–124; doi: 10.1038/nri3150
34.
KimberI, BasketterDA, GerberickGF, et al.Allergic contact dermatitis. Int Immunopharmacol. 2002; 2(2-3):201–211; doi: 10.1016/S1567-5769(01)00173-4
35.
MartinSF. The role of the innate immune system in allergic contact dermatitis. Allergol Select. 2017; 1(1):39–43; doi: 10.5414/ALX01274E
36.
YusufN, NastiTH, LongJA, et al.Protective role of toll-like Receptor 4 during the Initiation stage of cutaneous chemical carcinogenesis. Cancer Res. 2008; 68(2):615–622; doi: 10.1158/0008-5472.CAN-07-5219
37.
NaseemuddinM, IqbalA, NastiTH, et al.Cell mediated immune responses through TLR4 prevents DMBA-induced mammary carcinogenesis in mice. Int J Cancer. 2012; 130(4):765–774; doi: 10.1002/ijc.26100
38.
NakamuraN, Tamagawa-MineokaR, UetaM, et al.Toll-like Receptor 3 increases allergic and irritant contact dermatitis. J Invest Dermatol. 2015; 135(2):411–417; doi: 10.1038/jid.2014.402
39.
SilverbergNB, PelletierJL, JacobSE, et al.Nickel allergic contact dermatitis: Identification, treatment, and prevention. Pediatrics. 2020; 145(5); doi: 10.1542/peds.2020-0628
40.
KatsnelsonA. Nickel allergy tracked to a single receptor. Nature. 2010; doi: 10.1038/news.2010.407Published online August 15,
41.
SchmidtM, RaghavanB, MüllerV, et al.Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel. Nat Immunol. 2010; 11(9):814–819; doi: 10.1038/ni.1919
42.
AhlströmMG, ThyssenJP, WennervaldtM, et al.Nickel allergy and allergic contact dermatitis: A clinical review of immunology, epidemiology, exposure, and treatment. Contact Dermatitis. 2019; 81(4):227–241; doi: 10.1111/cod.13327
43.
SaitoM, ArakakiR, YamadaA, et al.Molecular mechanisms of nickel allergy. Int J Mol Sci. 2016; 17(2):202; doi: 10.3390/ijms17020202
44.
OblakA, PoharJ, JeralaR. MD-2 determinants of nickel and cobalt-mediated activation of human TLR4. PLoS One. 2015; 10(3):e0120583; doi: 10.1371/journal.pone.0120583
45.
RachmawatiD, BontkesHJ, VerstegeMI, et al.Transition metal sensing by Toll-like receptor-4: Next to nickel, cobalt and palladium are potent human dendritic cell stimulators. Contact Dermatitis. 2013; 68(6):331–338; doi: 10.1111/cod.12042
46.
MidanderK, WernerP, IsakssonM, et al.Cobalt nanoparticles cause allergic contact dermatitis in humans. Br J Dermatol. 2023; 188(2):278–287; doi: 10.1093/bjd/ljac043
47.
BockM, SchmidtA, BrucknerT, et al.Occupational skin disease in the construction industry. Br J Dermatol. 2003; 149(6):1165–1171; doi: 10.1111/j.1365-2133.2003.05748.x
48.
SedikAA, HassanA, SalamaA. Synergistic effect of arginine and Lactobacillus plantarum against potassium dichromate induced-acute liver and kidney injury in rats: Role of iNOS and TLR4/NF-κB signaling pathways. Iran J Basic Med Sci. 2023; 26(8):941–952; doi: 10.22038/IJBMS.2023.68855.15108
49.
GaspariAA. The role of keratinocytes in the pathophysiology of contact dermatitis. Immunol Allergy Clin North Am. 1997; 17(3):377–405; doi: 10.1016/S0889-8561(05)70316-7
SeongSY, MatzingerP. Hydrophobicity: An ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol. 2004; 4(6):469–478; doi: 10.1038/nri1372
53.
LaiY, Di NardoA, NakatsujiT, et al.Commensal bacteria regulate Toll-like receptor 3–dependent inflammation after skin injury. Nat Med. 2009; 15(12):1377–1382; doi: 10.1038/nm.2062
54.
BhaskaranN, CohenS, ZhangY, et al.TLR-2 signaling promotes IL-17A production in CD4+CD25+Foxp3+ Regulatory cells during oropharyngeal candidiasis. Pathogens. 2015; 4(1):90–110; doi: 10.3390/pathogens4010090
55.
ValinsW, AminiS, BermanB. The expression of toll-like receptors in dermatological diseases and the therapeutic effect of current and newer topical toll-like receptor modulators. J Clin Aesthet Dermatol. 2010; 3(9):20–29.
FrancoLM, GadkariM, HoweKN, et al.Immune regulation by glucocorticoids can be linked to cell type–dependent transcriptional responses. J Exp Med. 2019; 216(2):384–406; doi: 10.1084/jem.20180595
59.
BroeringR, MontagM, JiangM, et al.Corticosteroids shift the Toll-like receptor response pattern of primary-isolated murine liver cells from an inflammatory to an anti-inflammatory state. Int Immunol. 2011; 23(9):537–544; doi: 10.1093/intimm/dxr048
60.
Cury MartinsJ, MartinsC, AokiV, et al.Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev. 2015; 2015(7):CD009864; doi: 10.1002/14651858.CD009864.pub2
61.
ArayaAA, TasnifY. Tacrolimus.; 2023.
62.
AntigaE, VolpiW, TorchiaD, et al.Effects of tacrolimus ointment on Toll-like receptors in atopic dermatitis. Clin Exp Dermatol. 2011; 36(3):235–241; doi: 10.1111/j.1365-2230.2010.03948.x
63.
XieZ. Q, LiuL. L, YangG.-y, et al.[Effect of topical tacrolimus ointment on expression of Toll-like receptors 2 and 4 in lesional atopic dermatitis skin]. Beijing da Xue Xue Bao Yi Xue Ban = Ban. 2006; 38(4):420–423.
64.
ChurchM, ChurchD. Pharmacology of antihistamines. Indian J Dermatol. 2013; 58(3):219–224; doi: 10.4103/0019-5154.110832
65.
FajarJK. H1 antihistamines in allergic rhinitis: The molecular pathways of interleukin and toll - like receptor systems. JHSCI. 2016; 6(1):1; doi: 10.17532/jhsci.2016.272
66.
ParkCS, ChoJH, KangJM, et al.Levocetrizine has anti-inflammatory effects against Toll-like receptor (TLR)3 through the inhibition of Toll-IL-1 receptor (TIR)-domain-containing adapter inducing IFN-beta (TRIF) and receptor-interacting protein (RIP). Auris Nasus Larynx. 2011; 38(4):474–479; doi: 10.1016/j.anl.2010.12.008
67.
JeklerJ. Phototherapy of atopic dermatitis with ultraviolet radiation. Acta Derm Venereol Suppl (Stockh)). 1992; 171:1–37.
68.
AhmadI, SimanyiE, GurojiP, et al.Toll-Like receptor-4 deficiency enhances repair of UVR-induced cutaneous DNA damage by nucleotide excision repair mechanism. J Invest Dermatol. 2014; 134(6):1710–1717; doi: 10.1038/jid.2013.530
69.
ZhouH, HarbertsE, FishelevichR, et al.TLR4 acts as a death receptor for ultraviolet radiation (UVR) through IRAK-independent and FADD-dependent pathway in macrophages. Exp Dermatol. 2016; 25(12):949–955; doi: 10.1111/exd.13222
70.
SchmidtM, GoebelerM. Nickel allergies: Paying the Toll for innate immunity. J Mol Med (Berl)). 2011; 89(10):961–970; doi: 10.1007/s00109-011-0780-0
71.
LewisW, SimanyiE, LiH, et al.Regulation of ultraviolet radiation induced cutaneous photoimmunosuppression by Toll-like receptor-4. Arch Biochem Biophys. 2011; 508(2):171–177; doi: 10.1016/j.abb.2011.01.005
72.
ThatcherTH, LuzinaI, FishelevichR, et al.Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance. J Invest Dermatol. 2006; 126(4):821–831; doi: 10.1038/sj.jid.5700167
73.
SchwarzA, MaedaA, KernebeckK, et al.Prevention of UV radiation–induced immunosuppression by IL-12 is dependent on DNA repair. J Exp Med. 2005; 201(2):173–179; doi: 10.1084/jem.20041212
74.
WangJ, ZhangJ, WangJ, et al.Small-molecule modulators targeting toll-like receptors for potential anticancer therapeutics. J Med Chem. 2023; 66(10):6437–6462; doi: 10.1021/acs.jmedchem.2c01655
75.
GaoW, XiongY, LiQ, et al.Inhibition of toll-like receptor signaling as a promising therapy for inflammatory diseases: A journey from molecular to nano therapeutics. Front Physiol. 2017; 8:508; doi: 10.3389/fphys.2017.00508
76.
O’NeillLAJ, BryantCE, DoyleSL. Therapeutic targeting of toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev. 2009; 61(2):177–197; doi: 10.1124/pr.109.001073
FukushimaH, IwataY, WatanabeS, et al.TAK-242 ameliorates contact dermatitis exacerbated by IL-36 receptor antagonist deficiency. Sci Rep. 2020; 10(1):734; doi: 10.1038/s41598-020-57550-5
79.
BaiYR, YangWG, HouXH, et al.The recent advance of Interleukin-1 receptor associated kinase 4 inhibitors for the treatment of inflammation and related diseases. Eur J Med Chem. 2023; 258:115606; doi: 10.1016/j.ejmech.2023.115606
80.
SuzukiM, KatoC, KatoA. Therapeutic antibodies: Their mechanisms of action and the pathological findings they induce in toxicity studies. J Toxicol Pathol. 2015; 28(3):133–139; doi: 10.1293/tox.2015-0031
81.
SpillerS, ElsonG, FerstlR, et al.TLR4-induced IFN-γ production increases TLR2 sensitivity and drives Gram-negative sepsis in mice. J Exp Med. 2008; 205(8):1747–1754; doi: 10.1084/jem.20071990
82.
HattererE, ShangL, SimonetP, et al.A specific anti-citrullinated protein antibody profile identifies a group of rheumatoid arthritis patients with a toll-like receptor 4-mediated disease. Arthritis Res Ther. 2016; 18(1):224; doi: 10.1186/s13075-016-1128-5
83.
HedayatM, TakedaK, RezaeiN. Prophylactic and therapeutic implications of toll-like receptor ligands. Med Res Rev. 2012; 32(2):294–325; doi: 10.1002/med.20214
84.
PiszczatoskiCR, PowellJ. Topical clascoterone: The first novel agent for acne vulgaris in 40 years. Clin Ther. 2021; 43(10):1638–1644; doi: 10.1016/j.clinthera.2021.08.007
85.
ClarkR, KupperT. Old meets new: The interaction between innate and adaptive immunity. J Invest Dermatol. 2005; 125(4):629–637; doi: 10.1111/j.0022-202X.2005.23856.x
86.
ElshabrawyHA, EssaniAE, SzekaneczZ, et al.TLRs, future potential therapeutic targets for RA. Autoimmun Rev. 2017; 16(2):103–113; doi: 10.1016/j.autrev.2016.12.003
87.
FengY, YangS, MaY, et al.Role of Toll-like receptors in diabetic renal lesions in a miniature pig model. Sci Adv. 2015; 1(5):e1400183; doi: 10.1126/sciadv.1400183
88.
BirdL. A new ligand for TLR11. Nat Rev Immunol. 2005; 5(6):432–432; doi: 10.1038/nri1638
89.
KoblanskyAA, JankovicD, OhH, et al.Recognition of profilin by toll-like receptor 12 is critical for host resistance to toxoplasma gondii. Immunity. 2013; 38(1):119–130; doi: 10.1016/j.immuni.2012.09.016
